European veterinary practitioners are to receive guidance on the appropriate use of the fluoroquinolone group of antibiotics in treating a wide range of common diseases in companion animals.
The advice has been drawn up by the REQUEST team, a multinational and multidisciplinary group of experts which met for the third time last November. Their recommendations have been designed to help ensure the continued availability of this class of antibiotics in both veterinary and human medicine.
The REQUEST initiative aims to achieve a consensus on when and how to prescribe fluoroquinolones, based on a detailed assessment of published scientific data by its panel of nine acknowledged international experts. Following earlier meetings in Lyon and Vienna they have reached a stage in this ongoing project in which they can offer specific guidance on the use of fluoroquinolones in treating three important conditions in dogs: pyoderma, bacterial diseases of the upper respiratory tract and lower urinary tract infections. They will also be offering guidance on the appropriate use of this class of antibiotics in cats to avoid the development of retinal toxicities, which may occasionally result from treatment with one particular fluoroquinolone drug, enrofloxacin.
The guidance will be presented in papers to be submitted to those scientific journals which will be easily accessible to veterinary practitioners throughout Europe. Further papers will be produced and translated into the main European languages giving guidance on fluoroquinolones use in other important bacterial conditions in dogs and cats.
In the later stages of the project, the team will be highlighting priorities for future research and will use its influence to encourage collaborative studies involving the animal health industry, practitioners, veterinary schools and other research institutions, which will validate and redefine the current recommendations. They will also advise on studies which may provide the information needed in those clinical areas where there is currently insufficient published data on which to base any practical advice, such as the use of fluoroquinolones in minor companion animal species.
The REQUEST initiative is supported by Vetoquinol, a global supplier of fluoroquinolone medicines to the veterinary community. Further support is provided by the healthcare consultancy StratAdviser Ltd, which gives assistance on methodology and other scientific matters and also guarantees the independence of the expert group.